These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 20368635)

  • 1. The delayed-start study in Parkinson disease: can't satisfy everyone.
    Olanow CW; Rascol O
    Neurology; 2010 Apr; 74(14):1149-50. PubMed ID: 20368635
    [No Abstract]   [Full Text] [Related]  

  • 2. The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
    Montgomery EB
    Neurology; 2010 Nov; 75(21):1943; author reply 1944-5. PubMed ID: 21155188
    [No Abstract]   [Full Text] [Related]  

  • 3. The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
    Schwarzschild MA
    Neurology; 2010 Nov; 75(21):1943-4; author reply 1944-5. PubMed ID: 21098412
    [No Abstract]   [Full Text] [Related]  

  • 4. Rasagiline in Parkinson's disease.
    Schwarzschild MA
    N Engl J Med; 2010 Feb; 362(7):658; author reply 658-9. PubMed ID: 20187261
    [No Abstract]   [Full Text] [Related]  

  • 5. Delayed start, rapid solution?
    Korczyn AD; Vakhapova V
    Neuroepidemiology; 2010; 35(3):214. PubMed ID: 20664295
    [No Abstract]   [Full Text] [Related]  

  • 6. What is the clinical significance of the findings from the delayed-start trial of rasagiline in Parkinson's disease?
    Vanacore N
    Neuroepidemiology; 2010; 35(3):213. PubMed ID: 20664294
    [No Abstract]   [Full Text] [Related]  

  • 7. Reexamination of the TEMPO Study.
    Shults CW
    Arch Neurol; 2005 Aug; 62(8):1320; author reply 1321. PubMed ID: 16087778
    [No Abstract]   [Full Text] [Related]  

  • 8. Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
    Ahlskog JE; Uitti RJ
    Neurology; 2010 Apr; 74(14):1143-8. PubMed ID: 20368634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The delayed-start study design.
    D'Agostino RB
    N Engl J Med; 2009 Sep; 361(13):1304-6. PubMed ID: 19776413
    [No Abstract]   [Full Text] [Related]  

  • 10. Ginkgo biloba prevention trials: more than an ounce of prevention learned.
    Kaye J
    Arch Neurol; 2009 May; 66(5):652-4. PubMed ID: 19433666
    [No Abstract]   [Full Text] [Related]  

  • 11. Korn and Freidlin's misunderstanding of the null hypothesis significance testing procedure.
    Trafimow D; Rice S
    Am J Bioeth; 2011 Mar; 11(3):15-6. PubMed ID: 21400377
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to Drs. Olanow and Rascol.
    Ahlskog JE; Uitti RJ
    Neurology; 2010 Apr; 74(14):1151. PubMed ID: 20368636
    [No Abstract]   [Full Text] [Related]  

  • 13. "Disease-modification" trials in Parkinson disease: target populations, endpoints and study design.
    Rascol O
    Neurology; 2009 Feb; 72(7 Suppl):S51-8. PubMed ID: 19221315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to evaluate a dental article about harm.
    Jacob RF; Lloyd PM
    J Prosthet Dent; 2000 Jul; 84(1):8-16. PubMed ID: 10898835
    [No Abstract]   [Full Text] [Related]  

  • 15. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?
    Clarke CE
    Mov Disord; 2008 Apr; 23(6):784-9. PubMed ID: 18175348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: A randomized study of back school in women with chronic low back pain. Quality of life at three, six, and twelve months follow-up.
    Padua R; Bondi R; Ceccarelli E; Alviti F
    Spine (Phila Pa 1976); 2009 May; 34(12):1336. PubMed ID: 19455011
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.
    Hauser RA; Lew MF; Hurtig HI; Ondo WG; Wojcieszek J; Fitzer-Attas CJ;
    Mov Disord; 2009 Mar; 24(4):564-73. PubMed ID: 19086083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.
    Olanow CW; Hauser RA; Jankovic J; Langston W; Lang A; Poewe W; Tolosa E; Stocchi F; Melamed E; Eyal E; Rascol O
    Mov Disord; 2008 Nov; 23(15):2194-201. PubMed ID: 18932271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Slowing the progression of Alzheimer disease: methodologic issues.
    Leber P
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 5():S10-21; discussion S37-9. PubMed ID: 9348423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial.
    Levin BJ; Thompson G; Mitsumoto LH; Kaufmann P
    Neurology; 2006 Jun; 66(11):1786-7; author reply 1786-7. PubMed ID: 16769973
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.